Cost-effectiveness analysis of tisotumab vedotin shows modest benefits in patients with recurrent cervical cancer, suggesting economic viability.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Briceño-Casado et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: